The Trump administration has moved to ease access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr., and a UNLV physician is walking through the safety picture on local television. Dr. Marc Kahn, professor and chief of hematology at UNLV's Department of Internal Medicine at the Kirk Kerkorian School of Medicine, joined ARC Las Vegas and Evan Schreiber to explain the timeline.

The draft policy was posted online by Kennedy's Department of Health and Human Services. It covers a handful of injectable peptides promoted within the wellness industry for uses such as building muscle, healing injuries and boosting energy.

A draft written outside FDA

FDA scientific staffers had little input on the decision and opposed the changes, according to six people familiar with its development. The document was primarily written by officials at HHS, not at the agency that would normally own a question like this.

That detail is the story. A policy loosening access to injectable drugs, drafted around the scientists whose job is to assess injectable drugs, is a structural fact that no amount of debate about any individual peptide changes.

What the staffers warned

The pushback among FDA drug staffers was described as overwhelming. They warned the measure could undermine the agency's long-standing mission of keeping unsafe health products off the U.S. market, according to the people familiar with its development.

That is a broad objection rather than a compound-specific one. The reporting does not attribute a named safety finding about any particular peptide to those staffers.

Two weeks of comment

The government will take comments for two weeks before finalizing the measure. Two weeks is a short runway for a change this contested, and it is the only formal opening anyone outside HHS gets.

The Associated Press contributed to the report, under the headline that Kennedy eased access despite opposition from FDA scientists. CNN has also covered what the change would mean in practice.

The questions the draft leaves open

The peptides covered are described as unproven, and nothing in the reporting attaches a trial, an efficacy figure or a safety dataset to them. Easier access does not generate evidence, and the draft does not appear to require any.

What happens after the comment window closes is the thing to watch. Whether the final measure keeps the scope it has now, and whether FDA staff objections surface in the record, is still unsettled.